Septic Shock, Vasopressor Resistance

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Septic Shock, Vasopressor Resistance trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (3 shown)

Not Yet RecruitingPhase 3

NCT07569536

Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock

Septic shock is one of the most frequent reasons for admission to intensive care units and remains associated with a high mortality rate of approximatively 40%…

France360 participantsStarted 2026-09-01

Treatment: Dexmedetomidine 100 µg/mL, intravenous solution, Stardard care

TerminatedPhase 3

NCT03953677

Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock

Septic shock is common in patients admitted to intensive care and hospital mortality occurs in close to 50% of these patients. In half of the cases, death occur…

France32 participantsStarted 2019-10-27

Treatment: Dexmedetomidine 100 Mcg/mL Intravenous Solution, 5% glucose Infusion solution

UnknownPhase 3

NCT03038503

What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin

The ICU mortality rate of patients with septic shock was still high upto 54.1%.In first 6 hours of resuscitation, the goals of resuscitation in sepsis shock aft…

Thailand60 participantsStarted 2016-12

Treatment: Methylene Blue, Terlipressin